Analysis of Survival Modification by Furosemide Use in a Cohort of Hospitalized COVID-19 Patients with Severe or Critical Disease in Mexico: Due to Its Chemical Structure, Furosemide Is More than Just a Diuretic.
Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Janet Diaz-MartinezResearch Center in Minority Institutions, Robert Stempel College of Public Health, Florida International University, Miami, FL 33199, USA.ORCID 0000-0003-3295-4768
Wayne KotzkerFlorida Kidney Physicians, Panoramic Health Practice, Boca Raton, FL 33431, USA.
Martha A Mendoza-HernandezDepartment of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.ORCID 0000-0002-7646-0842
Rajdeep S GadhFlorida Kidney Physicians, Panoramic Health Practice, Coral Springs, FL 33071, USA.
Gustavo A Hernandez-FuentesDepartment of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.ORCID 0000-0003-4685-3095
Andrew BañuelosDepartment GME (General Medicine Education), Hospital Corporation of America Westside, Westside, FL 33324, USA.
José Guzmán-EsquivelClinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Colima 29883, Mexico.ORCID 0000-0002-6727-0051
Angelina HongDepartment GME (General Medicine Education), Hospital Corporation of America Westside, Westside, FL 33324, USA.
Osiris G Delgado-EncisoDepartment of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
Elizabeth Geyer-RobertsDepartment of Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova University, Fort Lauderdale, FL 33328, USA.
Margarita L Martinez-FierroMolecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico.ORCID 0000-0003-1478-9068
Iram P Rodriguez-SanchezMolecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolas de los Garza 66455, Mexico.ORCID 0000-0002-5988-4168
Idalia Garza-VelozMolecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico.
Luis M Canseco-ÁvilaDiagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula 30700, Mexico.ORCID 0000-0002-5694-3118
Ivan Delgado-EncisoDepartment of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.ORCID 0000-0001-9848-862X
Funding
Consejo Nacional de Humanidades, Ciencias y Tecnologías 319282
6 · The paper itself
Abstract
In the ongoing fight against Coronavirus Disease 2019 (COVID-19), researchers are exploring potential treatments to improve outcomes, especially in severe cases. This includes investigating the repurposing of existing medications, such as furosemide, which is widely available. This study aimed to evaluate the impact of furosemide on mortality rates among COVID-19 patients with severe or critical illness. We assessed a cohort of 515 hospitalized adults who experienced a high mortality rate of 43.9%. Using a multivariate analysis with adjusted risk ratios (AdRRs), factors like smoking (AdRR 2.48, 95% CI 1.53-4.01,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Analysis of Survival Modification by Furosemide Use in a Cohort of Hospitalized COVID-19 Patients with Severe or Critical Disease in Mexico: Due to Its Chemical Structure, Furosemide Is More than Just a Diuretic. · full record | OpenQuestion